Author:
Kapoor Akhil,Kumar Amit,Prabhash Kumar
Subject
Cancer Research,Oncology (nursing),Drug Guides,Ophthalmology
Reference6 articles.
1. Concurrent PIK3CA mutation: A cause for primary resistance to epidermal growth factor receptor tyrosine kinase inhibitors or an acquired phenomenon?;Verma;Cancer Res Stat Treat,2021
2. Comprehensive genomic profiling of lung cancer: A key to better clinical management;Gupta;Cancer Res Stat Treat,2021
3. Baa AK, Malik PS. PIK3CA alterations in non-small cell lung carcinoma: A puzzle yet to be solved. Cancer Res Stat Treat 2021;797-9.
4. Concurrent EGFR and PIK3CA mutations in non-small-cell lung cancer;Kapoor;Cancer Res Stat Treat,2021
5. Treatment of advanced non-small-cell lung cancer: First line, maintenance, and second line – Indian consensus statement update (Under the aegis of Lung Cancer Consortium Asia, Indian Cooperative Oncology Network, Indian Society of Medical and Pediatric Oncology, Molecular Oncology Society, and Association of Physicians of India);Prabhash;Cancer Res Stat Treat,2021